Genetic predisposition resulting in sinusoidal obstruction syndrome in a patient with resected sigmoid cancer on adjuvant oxaliplatin

BMJ Case Rep. 2016 Jan 4:2016:bcr2015212978. doi: 10.1136/bcr-2015-212978.

Abstract

A Chinese man who had undergone a curative high anterior resection for sigmoid cancer was administrated XELOX (capecitabine and oxaliplatin) as postoperative adjuvant chemotherapy. He subsequently developed sinusoidal obstruction syndrome (SOS) that resolved on discontinuation of XELOX treatment. Genetic evaluation determined that he had the GSTT1-null and GSTM1-null genotype, known to be an independent risk factor for developing oxaliplatin-induced SOS.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Capecitabine
  • Chemotherapy, Adjuvant
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives
  • Fluorouracil / adverse effects
  • Fluorouracil / analogs & derivatives
  • Genetic Predisposition to Disease*
  • Glutathione Transferase / genetics
  • Hepatic Veno-Occlusive Disease / chemically induced*
  • Hepatic Veno-Occlusive Disease / diagnosis
  • Hepatic Veno-Occlusive Disease / genetics
  • Humans
  • Male
  • Middle Aged
  • Organoplatinum Compounds / adverse effects*
  • Oxaliplatin
  • Oxaloacetates
  • Sigmoid Neoplasms / complications*
  • Sigmoid Neoplasms / surgery

Substances

  • Organoplatinum Compounds
  • Oxaloacetates
  • Oxaliplatin
  • Deoxycytidine
  • Capecitabine
  • glutathione S-transferase T1
  • Glutathione Transferase
  • glutathione S-transferase M1
  • Fluorouracil

Supplementary concepts

  • XELOX